🇺🇸

US SEC Filing Intelligence

· daily

HHS & Healthcare Contracts Intelligence — March 14, 2026

BARDA's $980M in biotech R&D contracts signal robust, long-term U.S. biodefense funding through 2032, with full obligations (base + options) exceeding $1.7B potential. MAPP Biopharmaceutical's bullish $185M award (47% outlayed, $907M upside) highlights small-cap viral therapeutics momentum, contrasting neutral nonprofit stability at Advanced Technology International ($14M of $795M outlayed). Investors should prioritize equity exposure in small biopharma over nonprofits amid early-stage execution variances.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 14, 2026

A single $75.8M VA contract to SDVOSB Richard Group LLC for EHRM infrastructure upgrades at Hines, IL, represents full federal obligation in hospital construction with performance through 2027-03-09, signaling targeted veteran healthcare spending. Neutral overall impact limits broader sector alpha due to small business set-aside, but provides revenue visibility amid zero outlays to date. Execution risks from firm-fixed-price structure warrant monitoring for cost overruns in this concentrated NAICS 236220 award.

1 total filings
· daily

Federal Professional Services Contracts — March 14, 2026

Lockheed Martin dominates with two sole-source Time & Materials contracts totaling $64.97M from US Coast Guard for Sea Commander engineering/C4ISR ($42.13M, bullish) and sustainment ($22.84M, neutral), locking in revenue through Apr 2026 despite $0 outlays to date. This concentration highlights entrenched positioning in DHS professional engineering services but flags execution delays after 3+ years. Investors gain visibility into steady defense services backlog amid sole-source favoritism.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — March 14, 2026

Five bullish contracts totaling $943M in obligations signal robust federal demand for IT systems design (NAICS 541512), with base+options ceiling exceeding $1.9B, providing multi-year revenue visibility through 2029. VA dominates with ~40% of value across two awards, underscoring priority on veteran-focused IT/DevSecOps. Small/disadvantaged businesses captured 3/5 awards via set-asides, highlighting competitive edges in federal procurement amid full/open competition wins by larger players.

5 total filings
· daily

New Federal Contractors — March 14, 2026

This period's $4.99B in new federal contracts is dominated by VA and HHS awards totaling ~$2.7B (54%), signaling robust demand for healthcare services, medical evaluations, and biotech R&D amid long-term commitments to 2032. Bullish signals prevail (12/15) for public firms like L3Harris ($814M NASA space tech) and Lockheed Martin ($65M DHS engineering), with private players capturing bulk via full competition wins. Option-heavy structures (~$3B+ potential upside across contracts) offer multi-year revenue expansion, though firm-fixed-price prevalence flags execution risks.

15 total filings
· daily

Significant Contract Modifications ($10M+) — March 14, 2026

This $4.99B batch of significant contract modifications signals robust federal spending on healthcare/IT services, particularly VA/HHS ($3.0B+ across 8 awards), providing multi-year revenue visibility to winners like TriWest ($820M health insurance) and L3Harris ($814M space tech). Bullish for large primes in health R&D, veteran services, and defense IT, with 12/15 signals positive, though firm-fixed-price structures and long durations (many to 2029+) flag execution risks. Neutral on nonprofits/small biz due to limited equity upside, but options/upside potential totals $2B+ across deals.

15 total filings
· daily

Contract Deobligations Alert — March 14, 2026

This week's $4.99B in federal contract obligations signal robust demand for healthcare services (VA/HHS ~$2.8B or 56%), space/defense, and IT, with 12 bullish signals dominated by long-term awards to TriWest, L3Harris, and BL Harbert exceeding $800M each. Institutional investors should prioritize large-cap exposure (L3Harris, Lockheed) and VA-aligned veteran-owned firms for revenue visibility through 2029+, while monitoring firm fixed price risks and low outlays ($1.9B or 38% disbursed). Neutral signals on nonprofits/small businesses limit equity upside but highlight sector funding stability.

15 total filings
· daily

Contract Option Exercises — March 14, 2026

This period's $4.99B in contract option exercises signals strong federal commitment to healthcare (VA/HHS ~$2.8B or 56%), IT services (~$1.1B or 22%), and defense/space systems, with 12/15 bullish awards dominated by full/open competition wins. Largest awards (> $400M) to TriWest, L3Harris, BL Harbert highlight revenue visibility through 2026-2032, though short-duration outliers like TriWest's $820M 1-month deal raise execution questions. Investors should prioritize VA/IT exposed large caps (L3Harris, Lockheed) and monitor option exercises for ~$2B+ upside across contracts.

15 total filings
· daily

All HHS Contracts — March 14, 2026

HHS awarded $1.04B in obligations across three contracts, with 94% ($980M) concentrated in BARDA biotech R&D for pandemic threats, signaling sustained federal prioritization. Two bullish small business awards to MAPP Biopharma ($185M obligation, $907M ceiling) and ThirdPacket ($64M obligation, $128M ceiling) highlight equity growth potential via options, contrasting neutral nonprofit funding to Advanced Technology International ($795M). Long durations to 2029-2032 underscore stable revenue but execution risks from low outlays (avg. 20%).

3 total filings
· daily

Mega Contracts Monitor ($100M+) — March 14, 2026

Nine mega contracts totaling $4.6B awarded or active, with 8 bullish signals dominated by VA ($1.58B across 4 contracts) and HHS/BARDA ($980M across 2), signaling robust federal healthcare and biotech spending through 2029+. Long-term performance periods (avg. 5+ years) provide revenue visibility, though firm fixed price structures (6/9) heighten execution risks amid low average outlays ($13-94% realized). Institutional investors should prioritize L3Harris (public, $814M NASA) and VA/IT specialists for multi-year upside via options exceeding $2B potential.

9 total filings
· daily

High-Value Federal Grants ($5M+) — March 14, 2026

This period's $4.99B in high-value federal contracts is dominated by healthcare/VA awards (e.g., $819M TriWest, $381M Veterans Evaluation), signaling robust demand for medical and IT services amid long-term commitments to 2029+. Defense primes like L3Harris ($814M NASA) and Lockheed Martin ($65M DHS combined) benefit from stable revenue in space and C4ISR, with significant option upside across portfolio (~$2.5B+ potential). Investors should prioritize public equities in aerospace/defense while monitoring execution risks from firm-fixed-price structures and $0 outlays on several large awards.

15 total filings
· daily

General Federal Contracts — March 14, 2026

This $4.99B batch of federal contracts signals robust U.S. government commitment to health services, IT, biotech R&D, and space/defense, with 12 bullish awards dominated by VA ($1.65B across 5 contracts) and HHS ($1.04B across 3). Top winners TriWest ($820M VA health insurance), L3Harris ($814M NASA space tech), and BL Harbert ($814M State construction) offer multi-year revenue visibility to 2029+. Investors should prioritize large-cap exposure (L3Harris, Lockheed) and monitor option exercises adding $2B+ potential upside across deals.

15 total filings
· daily

All NASA Contracts — March 14, 2026

NASA's $814M obligation to L3Harris for CRIS instrument engineering and services through 2029 provides high-confidence, long-term revenue stability in space vehicle components (PSC 1820). With $216M already outlayed and $833M base+options potential, this underscores NASA commitment amid execution risks from 19-year duration and $168M subawards. Institutional investors gain actionable bullish signal for L3Harris, offset by monitoring subcontractor performance and tech obsolescence.

1 total filings
· daily

Global High-Priority Regulatory Events — March 14, 2026

The 17 filings reveal a surge in high-priority distress events among Indian listed companies, dominated by insolvency proceedings (10/17), with 70% showing positive progress via settlements, unanimous approvals, and scheme sanctions, signaling potential turnarounds amid CIRP protections. Negative outliers include Reliance Communications' subsidiary fraud classification on ₹375 Cr pre-CIRP loans (₹125 Cr SBI), Tijaria Polypipes' new Bank of India insolvency petition, and Olympic Cards' ₹0.15 Cr loan default on ₹15.5 Cr facility. No aggregate period-over-period financial trends available, but specific metrics highlight distress like Olympic's ₹9.28 Cr bank borrowings and 100% creditor approvals in restructurings (e.g., Share India 99.8% equity votes). Open offers (Lykis, Satani Bearings) and minor regulatory actions (Manappuram ₹2.7L penalty) add neutral-to-positive M&A/takeover themes. Three medium-risk encumbrances (Anand Rathi Wealth, India Finsec, unknown) warrant monitoring. Portfolio implications: Bullish resolution momentum for alpha in distressed assets, bearish fraud/default risks for avoidance; key catalysts cluster March-April 2026.

17 high priority 17 total filings
· daily

New Drug Approvals (Original) — March 13, 2026

FDA approved 7 original ANDA generic drugs on March 9-10, 2026, all under standard review with no special designations, therapeutic areas, or indications specified. These routine approvals enable market entry for smaller sponsors but carry neutral investment signals due to commoditization and lack of premium positioning. Cross-cutting pattern: uniform low-impact generics signal steady but non-disruptive pipeline activity, warranting monitoring for sponsor portfolio accumulation amid pricing risks.

7 total filings
· daily

DHS Homeland Security Contracts — March 13, 2026

DHS awarded $823M across 4 contracts in border wall construction, immigration detention/security, and disaster support, signaling sustained federal spending priorities through 2028. All bullish signals highlight revenue visibility from fully or partially obligated values, with $560M (68%) concentrated in Texas border infrastructure. Investors should prioritize public parents Fluor Corp and CoreCivic for near-term cash flow from high outlays and options upside totaling ~$360M unexercised.

4 total filings
· daily

VA Healthcare & Services Contracts — March 13, 2026

VA Healthcare awarded $136.9M in obligations across two contracts (IT services and architectural design), signaling robust demand for digital and physical infrastructure upgrades with potential upside to $273.4M via options. General Dynamics IT benefits from 37% outlay ($29.5M) indicating steady cash flow to 2029, while Hellmuth, Obata & Kassabaum gains 19-year visibility to 2028 despite slow 2.6% outlay start. Firm-fixed-price terms introduce margin risks, but full/open competition awards to non-SB firms underscore sector stability for institutional exposure.

2 total filings
· daily

HHS & Healthcare Contracts Intelligence — March 13, 2026

HHS obligated $796M across two health R&D contracts, led by a dominant $724M BARDA biotech award to nonprofit Advanced Technology International, providing 7+ year spending visibility but no equity upside. Bullish signal from Technical Resources International's $73M (potential $337M) NIAID clinical research contract, with 50% of obligated funds already outlayed since 2024. Low average outlays (~10% of obligated value) highlight execution risks, while long-term horizons to 2030-2031 underscore sustained health preparedness trends warranting sector monitoring.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — March 13, 2026

Two firm-fixed-price federal contracts totaling $900M in NAICS 236220 (commercial/institutional building) provide committed revenues to non-small business constructors through 2028, signaling sustained U.S. government demand for border security and diplomatic infrastructure. Barnard Spencer JV's $561M Texas border wall and Caddell Construction's $339M Turkmenistan embassy represent full options exercised via open competition, with zero outlays to date implying phased funding. Investors gain clear bullish exposure to large-scale execution but must flag cost overrun and delay risks.

2 total filings